Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. Glenmark's Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC, NDA 205029.

According to IQVIATM sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 2038.60 as compared to the previous close of Rs. 1990.75. The total number of shares traded during the day was 13653 in over 1209 trades.

The stock hit an intraday high of Rs. 2042.00 and intraday low of 1992.10. The net turnover during the day was Rs. 27644923.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USALaunch EpinephrineInjection